MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY

The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: NAJIM, John, DESJARDINS, Cody, PICARIELLO, Tyler, SUBRAMANIAN, Romesh, QUINN, Brendan, ZANOTTI, Stefano, WEEDEN, Timothy, QATANANI, Mohammed
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator NAJIM, John
DESJARDINS, Cody
PICARIELLO, Tyler
SUBRAMANIAN, Romesh
QUINN, Brendan
ZANOTTI, Stefano
WEEDEN, Timothy
QATANANI, Mohammed
description The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK. La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023283620A8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023283620A8</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023283620A83</originalsourceid><addsrcrecordid>eNrjZPD2DQ129nFVCHEMcncN8fRzV3D29w3wcY1wDVZw9HNRCA0GMkI8XINc_d0U3PyDFEKCXB3B6nwj_UP8_TydFVwig0OC_AM8InkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkbGRhbGZkYGjhTFxqgB3Dy8T</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><source>esp@cenet</source><creator>NAJIM, John ; DESJARDINS, Cody ; PICARIELLO, Tyler ; SUBRAMANIAN, Romesh ; QUINN, Brendan ; ZANOTTI, Stefano ; WEEDEN, Timothy ; QATANANI, Mohammed</creator><creatorcontrib>NAJIM, John ; DESJARDINS, Cody ; PICARIELLO, Tyler ; SUBRAMANIAN, Romesh ; QUINN, Brendan ; ZANOTTI, Stefano ; WEEDEN, Timothy ; QATANANI, Mohammed</creatorcontrib><description>The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK. La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231102&amp;DB=EPODOC&amp;CC=WO&amp;NR=2023283620A8$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231102&amp;DB=EPODOC&amp;CC=WO&amp;NR=2023283620A8$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAJIM, John</creatorcontrib><creatorcontrib>DESJARDINS, Cody</creatorcontrib><creatorcontrib>PICARIELLO, Tyler</creatorcontrib><creatorcontrib>SUBRAMANIAN, Romesh</creatorcontrib><creatorcontrib>QUINN, Brendan</creatorcontrib><creatorcontrib>ZANOTTI, Stefano</creatorcontrib><creatorcontrib>WEEDEN, Timothy</creatorcontrib><creatorcontrib>QATANANI, Mohammed</creatorcontrib><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><description>The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK. La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPD2DQ129nFVCHEMcncN8fRzV3D29w3wcY1wDVZw9HNRCA0GMkI8XINc_d0U3PyDFEKCXB3B6nwj_UP8_TydFVwig0OC_AM8InkYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkbGRhbGZkYGjhTFxqgB3Dy8T</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>NAJIM, John</creator><creator>DESJARDINS, Cody</creator><creator>PICARIELLO, Tyler</creator><creator>SUBRAMANIAN, Romesh</creator><creator>QUINN, Brendan</creator><creator>ZANOTTI, Stefano</creator><creator>WEEDEN, Timothy</creator><creator>QATANANI, Mohammed</creator><scope>EVB</scope></search><sort><creationdate>20231102</creationdate><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><author>NAJIM, John ; DESJARDINS, Cody ; PICARIELLO, Tyler ; SUBRAMANIAN, Romesh ; QUINN, Brendan ; ZANOTTI, Stefano ; WEEDEN, Timothy ; QATANANI, Mohammed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023283620A83</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>NAJIM, John</creatorcontrib><creatorcontrib>DESJARDINS, Cody</creatorcontrib><creatorcontrib>PICARIELLO, Tyler</creatorcontrib><creatorcontrib>SUBRAMANIAN, Romesh</creatorcontrib><creatorcontrib>QUINN, Brendan</creatorcontrib><creatorcontrib>ZANOTTI, Stefano</creatorcontrib><creatorcontrib>WEEDEN, Timothy</creatorcontrib><creatorcontrib>QATANANI, Mohammed</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAJIM, John</au><au>DESJARDINS, Cody</au><au>PICARIELLO, Tyler</au><au>SUBRAMANIAN, Romesh</au><au>QUINN, Brendan</au><au>ZANOTTI, Stefano</au><au>WEEDEN, Timothy</au><au>QATANANI, Mohammed</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY</title><date>2023-11-02</date><risdate>2023</risdate><abstract>The present application relates to oligonucleotides (e.g., antisense oligonucleotides such as gapmers) designed to target DMPK RNAs and targeting complexes for delivering the oligonucleotides to cells (e.g., muscle cells) and uses thereof, particularly uses relating to treatment of disease. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DMPK. La présente demande concerne des oligonucléotides (par exemple, des oligonucléotides antisens tels que des gapmères) conçus pour cibler des ARN DMPK et des complexes de ciblage pour administrer les oligonucléotides à des cellules (par exemple, des cellules musculaires) et leurs utilisations, en particulier des utilisations se rapportant au traitement de maladies. Selon certains modes de réalisation, l'agent de ciblage musculaire se lie de manière spécifique à un récepteur de surface cellulaire d'internalisation sur des cellules musculaires. Dans certains modes de réalisation, la charge utile moléculaire inhibe l'expression ou l'activité de DMPK.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2023283620A8
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
title MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T04%3A38%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAJIM,%20John&rft.date=2023-11-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023283620A8%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true